DK2443104T3 - Disubstituerede phthalazin-hedgehog-sti-antagonister - Google Patents
Disubstituerede phthalazin-hedgehog-sti-antagonisterInfo
- Publication number
- DK2443104T3 DK2443104T3 DK10726756.9T DK10726756T DK2443104T3 DK 2443104 T3 DK2443104 T3 DK 2443104T3 DK 10726756 T DK10726756 T DK 10726756T DK 2443104 T3 DK2443104 T3 DK 2443104T3
- Authority
- DK
- Denmark
- Prior art keywords
- hedgehog
- sti
- antagonists
- disubstituted phthalazine
- phthalazine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21862809P | 2009-06-19 | 2009-06-19 | |
| PCT/US2010/038568 WO2010147917A1 (en) | 2009-06-19 | 2010-06-15 | Disubstituted phthalazine hedgehog pathway antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2443104T3 true DK2443104T3 (da) | 2013-05-06 |
Family
ID=42332981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10726756.9T DK2443104T3 (da) | 2009-06-19 | 2010-06-15 | Disubstituerede phthalazin-hedgehog-sti-antagonister |
Country Status (35)
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA102250C2 (ru) * | 2008-04-29 | 2013-06-25 | Эли Лилли Энд Компани | Двухзамещенные фталазины - антагонисты проводящего пути hedgehog |
| EP2364185B1 (en) * | 2008-11-03 | 2013-05-22 | Eli Lilly And Company | Disubstituted phthalazine hedgehog pathway antagonists |
| MX2011005176A (es) * | 2008-11-17 | 2011-05-30 | Lilly Co Eli | Antagonistas de la trayectoria hedgehog de piridazinas tetrasustituidas. |
| CA2743483C (en) | 2008-11-17 | 2014-03-11 | Eli Lilly And Company | Tetrasubstituted pyridazine hedgehog pathway antagonists |
| AR077014A1 (es) | 2009-06-19 | 2011-07-27 | Lilly Co Eli | Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer |
| WO2012127441A1 (en) | 2011-03-23 | 2012-09-27 | Semorex Technologies Ltd. | Treatment of proliferative disorders with a chemiluminescent agent |
| GB201309508D0 (en) * | 2013-05-28 | 2013-07-10 | Redx Pharma Ltd | Compounds |
| GB201311953D0 (en) * | 2013-07-03 | 2013-08-14 | Redx Pharma Ltd | Compounds |
| WO2015073691A1 (en) | 2013-11-14 | 2015-05-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treating cancer by activation of bmp signaling |
| CN105017140B (zh) * | 2014-04-28 | 2017-12-29 | 复旦大学 | 邻氨基苯甲酰胺化合物及其制备方法和用途 |
| GB2528298A (en) * | 2014-07-16 | 2016-01-20 | Redx Pharma Plc | Compounds |
| CN105985320B (zh) * | 2015-02-11 | 2018-10-26 | 复旦大学 | 苄基酞嗪化合物及其制备方法和用途 |
| CN105985321B (zh) * | 2015-02-11 | 2018-10-26 | 复旦大学 | 吡唑酞嗪化合物及其制备方法和用途 |
| CN105985319B (zh) * | 2015-02-11 | 2019-02-26 | 复旦大学 | 芳基酞嗪化合物及其制备方法和用途 |
| CA2988289C (en) | 2015-06-04 | 2023-12-05 | PellePharm, Inc. | Topical formulations for delivery of hedgehog inhibitor compounds and use thereof |
| WO2016196879A1 (en) | 2015-06-05 | 2016-12-08 | Dana-Farber Cancer Institute, Inc. | Compounds and methods for treating cancer |
| ES3057783T3 (en) | 2016-03-15 | 2026-03-04 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases |
| CN106279114B (zh) * | 2016-08-04 | 2019-01-29 | 东南大学 | 一种Taladegib的合成方法 |
| US10548908B2 (en) * | 2016-09-15 | 2020-02-04 | Nostopharma, LLC | Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification |
| CN106831718B (zh) * | 2016-12-30 | 2019-05-07 | 上海科技大学 | 平滑受体配体及其应用 |
| JP7323457B2 (ja) | 2017-05-18 | 2023-08-08 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 肥満細胞疾患の処置のための方法及び医薬組成物 |
| EP4173639A4 (en) | 2020-06-26 | 2024-03-13 | RaQualia Pharma Inc. | METHOD FOR SELECTING A CANCER PATIENT FOR WHICH COMBINATION THERAPY OF A RETINOID AND A CANCER TREATMENT AGENT WILL BE EFFECTIVE, AND COMBINATION DRUG OF A RETINOID AND A CANCER TREATMENT AGENT |
| US12605377B2 (en) | 2020-10-13 | 2026-04-21 | Endeavor Biomedicines, Inc. | Methods of treating fibrosis |
| JP2023546536A (ja) * | 2020-10-13 | 2023-11-02 | エンデバー バイオメディシンズ， インコーポレイテッド | 線維症を処置する方法 |
| WO2025188802A1 (en) | 2024-03-05 | 2025-09-12 | Endeavor Biomedicines, Inc. | Methods of improving lung function |
| WO2025189041A1 (en) * | 2024-03-07 | 2025-09-12 | Endeavor Biomedicines, Inc. | Methods of treating fibrosis |
| WO2025242197A1 (zh) * | 2024-05-24 | 2025-11-27 | 成都思倍博医药科技有限公司 | 氘代的Hedgehog通路SMO受体抑制剂 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN148482B (https=) * | 1977-06-03 | 1981-03-07 | Pfizer | |
| ATE203534T1 (de) | 1996-01-15 | 2001-08-15 | Janssen Pharmaceutica Nv | Angiogenesis hemmende pyridazinamine |
| IL138645A0 (en) | 1998-04-09 | 2001-10-31 | Univ Johns Hopkins Med | Use of steroidal alkaloid derivatives as inhibitors of hedghog signalling pathways |
| CA2376210A1 (en) | 1999-06-08 | 2000-12-14 | Lorantis Limited | Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway |
| JP4658473B2 (ja) * | 2001-07-27 | 2011-03-23 | キュリス，インコーポレイテッド | ヘッジホッグシグナル伝達経路メディエーター、それに関連した組成物及び利用 |
| DE60322869D1 (de) | 2002-04-22 | 2008-09-25 | Univ Johns Hopkins | Modulatoren von hedgehog signalpfaden, zusammensetzungen und verwandte verwendungen |
| AU2003265853A1 (en) | 2002-08-29 | 2004-03-19 | Curis, Inc. | Hedgehog antagonists, methods and uses related thereto |
| US8067608B2 (en) | 2003-09-29 | 2011-11-29 | The Johns Hopkins University | Hedgehog pathway antagonists |
| TW200533356A (en) | 2004-02-24 | 2005-10-16 | Mitsubishi Pharma Corp | Fused pyridazine derivatives |
| EP1745039A4 (en) | 2004-05-08 | 2009-07-22 | Neurogen Corp | 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES |
| DK1789390T3 (da) | 2004-09-02 | 2012-02-27 | Genentech Inc | Pyridyl-inhibitorer af hedgehog-signalering |
| EP1900731A1 (de) * | 2006-09-07 | 2008-03-19 | Bayer Schering Pharma Aktiengesellschaft | N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren |
| PE20090188A1 (es) * | 2007-03-15 | 2009-03-20 | Novartis Ag | Compuestos heterociclicos como moduladores de la senda de hedgehog |
| US8153633B2 (en) * | 2007-06-25 | 2012-04-10 | Amgen Inc. | Phthalazine compounds, compositions and methods of use |
| WO2009035568A1 (en) | 2007-09-07 | 2009-03-19 | Amgen Inc. | Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling |
| CA2709203A1 (en) * | 2007-12-13 | 2009-06-18 | Siena Biotech S.P.A. | Hedgehog pathway antagonists and therapeutic applications thereof |
| UA102250C2 (ru) | 2008-04-29 | 2013-06-25 | Эли Лилли Энд Компани | Двухзамещенные фталазины - антагонисты проводящего пути hedgehog |
| US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
| AU2009279760B2 (en) * | 2008-08-04 | 2012-07-12 | Amgen Inc. | Aurora kinase modulators and methods of use |
| EP2364185B1 (en) | 2008-11-03 | 2013-05-22 | Eli Lilly And Company | Disubstituted phthalazine hedgehog pathway antagonists |
| CA2743483C (en) | 2008-11-17 | 2014-03-11 | Eli Lilly And Company | Tetrasubstituted pyridazine hedgehog pathway antagonists |
| MX2011005176A (es) | 2008-11-17 | 2011-05-30 | Lilly Co Eli | Antagonistas de la trayectoria hedgehog de piridazinas tetrasustituidas. |
| AR077014A1 (es) | 2009-06-19 | 2011-07-27 | Lilly Co Eli | Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer |
-
2010
- 2010-06-08 AR ARP100102003A patent/AR077014A1/es active IP Right Grant
- 2010-06-10 JO JO2010188A patent/JO2931B1/en active
- 2010-06-11 TW TW099119158A patent/TWI385165B/zh not_active IP Right Cessation
- 2010-06-15 MX MX2011014029A patent/MX2011014029A/es active IP Right Grant
- 2010-06-15 CA CA2764542A patent/CA2764542C/en not_active Expired - Fee Related
- 2010-06-15 UA UAA201114996A patent/UA106755C2/uk unknown
- 2010-06-15 EA EA201270049A patent/EA019059B1/ru not_active IP Right Cessation
- 2010-06-15 SI SI201030200T patent/SI2443104T1/sl unknown
- 2010-06-15 MY MYPI2011006137A patent/MY156667A/en unknown
- 2010-06-15 SG SG2011094190A patent/SG177289A1/en unknown
- 2010-06-15 WO PCT/US2010/038568 patent/WO2010147917A1/en not_active Ceased
- 2010-06-15 CN CN201080027189.3A patent/CN102459233B/zh active Active
- 2010-06-15 PE PE2011002119A patent/PE20121050A1/es active IP Right Grant
- 2010-06-15 HR HRP20130408AT patent/HRP20130408T1/hr unknown
- 2010-06-15 DK DK10726756.9T patent/DK2443104T3/da active
- 2010-06-15 AU AU2010260244A patent/AU2010260244B2/en not_active Ceased
- 2010-06-15 NZ NZ596882A patent/NZ596882A/xx not_active IP Right Cessation
- 2010-06-15 PL PL10726756T patent/PL2443104T3/pl unknown
- 2010-06-15 EP EP10726756.9A patent/EP2443104B1/en active Active
- 2010-06-15 US US12/815,439 patent/US8273742B2/en active Active
- 2010-06-15 KR KR1020117030157A patent/KR101389165B1/ko not_active Expired - Fee Related
- 2010-06-15 BR BRPI1011601A patent/BRPI1011601A2/pt not_active Application Discontinuation
- 2010-06-15 ES ES10726756T patent/ES2409054T3/es active Active
- 2010-06-15 MA MA34455A patent/MA33363B1/fr unknown
- 2010-06-15 PT PT107267569T patent/PT2443104E/pt unknown
- 2010-06-15 JP JP2012516178A patent/JP5596139B2/ja active Active
-
2011
- 2011-11-22 ZA ZA2011/08587A patent/ZA201108587B/en unknown
- 2011-11-24 IL IL216599A patent/IL216599A/en not_active IP Right Cessation
- 2011-11-29 HN HN2011003139A patent/HN2011003139A/es unknown
- 2011-12-07 TN TNP2011000627A patent/TN2011000627A1/en unknown
- 2011-12-08 CR CR20110658A patent/CR20110658A/es unknown
- 2011-12-13 DO DO2011000386A patent/DOP2011000386A/es unknown
- 2011-12-14 CL CL2011003147A patent/CL2011003147A1/es unknown
- 2011-12-16 EC EC2011011541A patent/ECSP11011541A/es unknown
- 2011-12-22 CO CO11177210A patent/CO6480932A2/es not_active Application Discontinuation
-
2012
- 2012-08-21 US US13/590,481 patent/US9000023B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2443104T3 (da) | Disubstituerede phthalazin-hedgehog-sti-antagonister | |
| BRPI1008774A2 (pt) | espiroamida substituída | |
| DK2411442T4 (da) | Umættet polyesterresin | |
| DE112010004215A5 (de) | Hydrostataktor | |
| EP2469625A4 (en) | OMNIBUS BAR | |
| EP2445547A4 (en) | CATHETERISM SYSTEM | |
| EP2491340A4 (en) | TELEMETRY PHOTOGRAPHIC APPARATUS | |
| EP2509489A4 (en) | SPRINKLER FOR EARLY HEEL REMOVAL | |
| DK2430035T3 (da) | Uracylspipooxetannukleosider | |
| BR112012000657A2 (pt) | novos azabicilohexanos | |
| DK2364185T3 (da) | Disubstituerede phthalazin-hedgehog-pathway-antagonister | |
| DE112010002728A5 (de) | Turboinhalator | |
| DE112010004249A5 (de) | Spindelaktor | |
| DE112009005323A5 (de) | Hebelarmprüfmaschine | |
| EP2446176A4 (en) | CYLINDER SEAL | |
| EP2415046C0 (en) | SHOULDER BRACKET | |
| BR112012004964A2 (pt) | girocóptero | |
| BRPI1008070A2 (pt) | tricianoboratos | |
| EP2409976A4 (en) | GLYCINE TRANSPORTER INHIBITOR | |
| DK2483126T3 (da) | Skinnekøretøj | |
| DE112010004865T8 (de) | Lamellennassreibkupplung | |
| DK2506968T3 (da) | Faujasit-zeolit | |
| DE112010003255A5 (de) | Fördergutverteiler | |
| EP2454221A4 (en) | cineole | |
| EP2398476A4 (en) | Policosanol nanoparticles |